Prof. Dr. Ulus Ali Şanlı

1987-1989                  General Practitioner

                                    Tuzluca /Kars, Turkey

1994-1995                  Internal Medicine specialist

                                    Kandıra/ İzmit, Turkey

1995-2023                  Ege University Medical School

                                    İzmir, Turkey

ARTICLES

1. Ulus Ali Sanli, Ruchan Uslu, Canfeza Sezgin, Bulent Karabulut, Erdem Goker. Docetaxel: A First Choice in the Management of Anthracycline-Resistant Metastatic Breast Cancer. Journal of B.U.O.N, 5: 399-403,2000.

2.  Ruchan Uslu, Ulus Ali Sanli, Canfeza Sezgin, Bulent Karabulut, Serdar B. Omay, Erdem Goker. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clinical Cancer Research, 6: 4957-4964, 2000.

3.  Safak Yuksel, Guray Saydam, Ruchan Uslu, Ulus Ali Sanli, Ender Terzioglu, Filiz Buyukececi, Serdar Bedii Omay. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leukemia Research, Apr; 26(4): 391-398, 2002.

4.  Ulus Ali Sanli, Ruchan Uslu, Bulent Karabulut, Canfeza Sezgin, Guray Saydam, Serdar Bedii Omay, Erdem Goker. Which dosing scheme is suitable for the taxanes? An in vitro model. Archives of Pharmacal Research  Aug; 25 (4): 550-5, 2002.

5.  Ruchan Uslu, Ulus Ali Sanli, Yilmaz Dikmen, Bulent Karabulut, Aydin Ozsaran, Canfeza Sezgin, Gamze Goksel Muezzinoglu, Serdar Bedii Omay, Erdem Goker. Paclitaxel chemotherapy and IL-8 interaction in ovarian cancer. International Journal of Gynecological Cancer (In Press).

6.  Ulus Ali Sanli, Ruchan Uslu, Bulent Karabulut, Canfeza Sezgin, Nur Selvi, Hikmet Hakan  Aydin, Guray Saydam, Erdem Goker, Serdar Bedii Omay. Alterations in the activity and expression of serine/ threonine protein phosphatases during all trans retinoic acid-induced apoptosis of breast cancer cells. Oncol Rep 10(6):2083-8. 2003.

7.  Erdem Goker, Ulus A. Sanli, Yildiray Yuzer, Ruchan Uslu, Bulent Karabulut, Ahmet Memis, Ahmet Coker, Ali  Mentes. Bioembolisation For Unresectable Hepatocellular Carcinoma: Preliminary Results Of A Translational Research Study. Journal of Experimental & Clinical Cancer Research (In press).

8.  Gulperi Oktem , Bulent Karabulut , Nur Selvi, Canfeza Sezgin, Ulus Ali Sanli, Ruchan Uslu, Mine Ertem Yurtseven , Serdar Bedii Omay. Differential Effects Of Doxorubicin And Docetaxel On Nitric Oxide Production And Inducible Nitric Oxide Synthase Expression In Mcf-7 Human Breast Cancer Cells. Oncology Research 14: 381-386, 2004.

9.  Zeynep Burak, Jean-Luc Moretti, Özden Ersoy, Ulus Sanlı, Mehmet Kantar, Feyzi Tamgac, Gülçin Başdemir. ^99mTc-MIBI Imaging as a Predictor of Therapy Response in Osteosarcoma Compared with Multidrug Resistance-Associated Protein and P-Glycoprotein Expression. The Journal of Nuclear Medicine, Sep;44(9):1394-1401, 2003.

10.  Karasulu YH, Karabulut B, Kantarcı G, Özgüney I, Sezgin C, Sanli UA, Göker E. Preperation of Arsenic Trioxide Loaded Microemulsion and Its Enhanced Cytotoxicity on MCF-7 Breast Carcinoma Cell Line. Drug Delivery. (In Press)

ABSTRACTS

1. Uslu R, Sezgin C, Karabulut B, Sanli UA, Tobu M, Saydam G, Buyukkececi F, Omay SB, Goker E. Arsenic trioxide-mediated cytotoxicity in prostate and ovarian carcinoma lines. Molecular Targets and Cancer Therapeutics , Discovery, Development, and Clinical Validation. November 16-19, 1999, Washington DC, USA. Proceedings of the AACR-NCI-EORTC International Conference: p: 55 (Abstract No: 271), 1999.

2.  Uslu R, Ozsaran A, Sanli UA, Dikmen Y, Goker ENT, Goker E. The effect of Taxol treatment on serum IL-8 levels in patients with ovarian carcinoma. Molecular Targets and Cancer Therapeutics , Discovery, Development, and Clinical Validation. November 16-19, 1999, Washington DC, USA. Proceedings of the AACR-NCI-EORTC International Conference: p: 80 (Abstract No: 394), 1999.

3.  Omay SB, Sanli UA, Uslu R, Sezgin VC, Karabulut B, Selvi N, Aydin HH, Saydam G, Goker E, Buyukkececi F. Alterations in the activity of serine/threonine protein phosphatases during ATRA-induced apoptosis of human breast cancer cells. 6th International Symposium on Predictive Oncology&Intervention Strategies Paris February 9-12, 2002. Cancer Detection and Prevention 2002 Symposium Volume, S-97 (Abstract No: 170), 2002.

4.  Sanli UA, Uslu R, Karabulut B, Sezgin VC, Saydam G, Omay SB, Buyukkececi F, Goker E. Which dosing scheme is suitable for the taxanes (Oral Presentation). 6th International Symposium on Predictive Oncology&Intervention Strategies Paris February 9-12, 2002. Cancer Detection and Prevention 2002 Symposium Volume, S-178 (Abstract No: 462), 2002.

5.  G. Öktem, B. Karabulut, N. Selvi, C. Sezgin, U.A.Şanlı, R. Uslu, A. Uysal, M.E. Yurtseven, S.B. Omay. Differantial induction of İNOS by doxorubucin and docetaxel in MCF-7 cell line. The 7th World Congress on Advances in Oncology, 5th International Symposium on Molecular Medicine, October 10-12, 2002, Crete, Greece. International Journal of Molecular Medicine, Volume 10, suppl 1, S-24 (Abstract No: 179), 2002.

6.  Murat Dayangac, Yildiray Yuzer, Erdem Goker, Ulus Sanli, Bulent Karabulut, Canfeza Sezgin. Lipiodol as an Antitumor Agent: in vitro Study in Human Hepatocellular Carcinoma HEPG2 Cells. 12th World Congress of the International Association of Surgeons and Gastroenterologists, October/November, 2002. Hepato-Gastroenterelogy, Volume 49, suppl II, Abstract No: 340, 2002.

7.  G.Görümlü, B. Karabulut, V.C. Sezgin, U.A. Sanli, G.G. Muezzinoglu, E. Göker. Treatment of Advanced GEP Tumors with Fluorouracil (FU), Interferon alpha 2b (IFN) and Octreotide (SMS). Somatostatin Receptor Physiology and Targets for Somatostatin Analogue Therapy (Investigator meeting), October 31- November 2, 2002, Barcelona, Spain. European Journal of Endocrinology, Volume 148, suppl 1, Abstract No: 301, 2003.

8.  M. Işık, B. Karabulut, V.C. Sezgin, U.A. Sanli, G.G. Muezzinoglu, E. Göker. Prevention of Irinotecan (IRI) Induced Delayed Diarrhea by Octreotide (SMS). Somatostatin Receptor Physiology and Targets for Somatostatin Analogue Therapy (Investigator meeting), October 31- November 2, 2002, Barcelona, Spain. European Journal of Endocrinology, Volume 148, suppl 1, Abstract No: 401, 2003.

9.  B. Karabulut, N. Selvi, U.A. Sanli, V.C. Sezgin, , G.G. Muezzinoglu, E. Göker. Dual Effect of Octreotide on Du-145 Prostate Carcinoma Cell Line : From Growth Proliferation To Reversal of Chemoreristance. Somatostatin Receptor Physiology and Targets for Somatostatin Analogue Therapy (Investigator meeting), October 31- November 2, 2002, Barcelona, Spain. European Journal of Endocrinology, Volume 148, suppl 1, Abstract No: 402, 2003.